Tag Archives: ceo

A Canadian Fundraising CEO’s Success at RESI

22 Feb

Anton Neschadim

An interview with Anton Neschadim, CEO, ImmunoBiochem
– By Chris Cummings, Senior Marketing Manager, LSN

Chris Cummings

Chris Cummings: What is your background, and how long have you been working in the life science space?

Anton Neschadim: I am a scientist-entrepreneur. I have a very deep, multi-disciplinary science background that I ultimately combined with a business degree, all from the University of Toronto. I am a lateral thinker, and as such always strived to be a subject-matter expert across multiple areas. And so, contrary to the traditional path of specialization in academia, I wanted to become a problem solver and innovator, and sought to master additional disciplines with every degree – chemistry, physics, immunology, cancer research, regenerative medicine. I believe that being able to draw on knowledge from multiple disciplines is key to generating creative insights. I transitioned into industry eight years ago, in the final year of my PhD, and took up a drug development role in a biologics program, while continuing to work in an academic lab evenings and weekends to amass more than 25 manuscripts and patents. Three years ago, I have focused on leading ImmunoBiochem with an exciting novel biologics program.

Chris Cummings: Are you currently fundraising? What previous financing or milestones has your company achieved (that you can disclose)?

Anton Neschadim: We are always fundraising, and are targeting to close another round led by current investors and partners in March. Our first deal was with one of the RESI sponsors and helped us develop fully-human antibody molecules for our lead target, and the subsequent angel-led round allowed us to develop a lead that we showed to be both efficacious and safe in preclinical animal tumor models. This new round will take our lead molecule into large animal studies, but we are eager to get into the clinic and are looking for additional capital to get us there.

Chris Cummings: How many RESI conferences have you attended previously, and when was your first event? Was ImmunoBiochem fundraising at the time?

Anton Neschadim: I have now attended three RESI conferences with the goal of raising funds every time – two in our hometown of Toronto, and the latest RESI during the JP Morgan healthcare week in San Francisco. We have closed a deal or round subsequent to each conference, and are on track to closing another round of financing following RESI in San Francisco. RESI has been extremely helpful for connecting with smart early-stage capital and learning how to better develop and tell our story to a broad range of investors. You know you have done well when you have new investors reaching out to you to learn more.

Chris Cummings: What components of RESI do you find most valuable? Do you spend most your time in partnering, or try to attend panels as well? When you participated in the Innovation Challenge, what aspects did you find beneficial?

Anton Neschadim: I tend to spend at least half of my day in one-on-one meetings, and then network with investors free-form outside of that. Panels and different tracks can help you be more targeted with the latter. I find the half-hour partnering format to be very optimal – just the right amount of time to make a connection with the investor, tell your story, answer questions, and for you to learn more about the investor’s interests and ask for feedback. The Innovation Challenge provides great exposure and is like real fundraising. It helps to have a team and to ultimately hold as many meaningful conversations as possible.

Chris Cummings: What advice can you give to other fundraising entrepreneurs attending RESI? For example, do you have any suggestions on mastering partnering, or perhaps maximizing your visibility in the Innovation Challenge?

Anton Neschadim: Visibility and being able to highlight your novelty and differentiation are paramount. What I found to be most useful is to have a team on the ground. It is great to have at least one person to move around the event, strike up conversations and bring people to your poster, while another is taking one-on-one meetings. When it comes to one-on-one meetings: register early and start requesting meetings as soon as partnering opens or even before that – spots fill up really fast. Do your research and target the right investors, avoid generic or overly long messaging, and manage time efficiently during the one-on-one meetings. The main goal is to get a second meeting or follow up.

About ImmunoBiochem

ImmunoBiochem is addressing significant unmet needs in oncology by developing highly-selective biological therapeutics. The majority of targeted biologics, which are focused on identifying and targeting unique features on the surface of cancer cells, face the challenge of tumor heterogeneity and general lack of selective tumor antigens, particularly as more potent platforms are utilized. CAR-T therapies are very exciting, with a single CAR-T cell being able to terminate from hundreds to thousands of cancer cells, but the current generation is extremely limited by very few suitable targets, such as CD19. The second generation of CAR-T therapies in the clinic will have to find a way to derive that selectivity from other mechanisms. To circumvent these challenges of surface-targeted biologics and cell therapies, ImmunoBiochem is solving this problem by combining a highly targeted and precise therapeutics platform – antibody-drug conjugates or ADCs – and non-traditional targets in the secretome of cancer cells that are amplified in the tumor microenvironment. ImmunoBiochem has defined a novel class of targets by isolating proteins with specific properties that are necessary to achieve selective and efficacious targeting of tumors with ADCs.  ImmunoBiochem was the original inventor of this technology and has tested this concept within an academic institute, and then developed a lead human antibody molecule in collaboration with the University of Toronto. Today we are supported by multiple organizations, including Johnson & Johnson Innovation (JLABS), where ImmunoBiochem is based, CCAB (the Centre for the Commercialization of Antibodies and Biologics), our key development partner and investor, OBIO, through membership and the CAAP program, and H2i at the University of Toronto.

When Raising Capital, CEOs Should Understand the LSN Value Proposition

22 Feb

By Skylar Jacobs, Business Development Manager, LSN

As Next Phase discussed two weeks ago, the world of early stage biotech and medtech investment is far less than straightforward and CEOs often have limited resources for learning where they fit into the capital landscape. In this article, we’ll look more closely at how LSN designed the LSN Investor Platform to address this problem.

Finding and Connecting with Investors that are a Fit for Your Company

LSN has found that the biggest difficulty for fundraising executives is identifying active investors that are a fit for their stage of development and product.  When raising a seed or series A financing, most executives go straight to a few brand name VCs and angel groups in their backyard, and, mistakenly, think this is going to get the job done. The reality is that fundraising is a numbers game, and there are thousands of groups across the world that are not currently known to the fundraising team, but may be a great fit for your venture. The problem is how to efficiently identify these groups, if they are a fit and, most importantly, how to reach them.

Global Matching Platform

Through this outreach, LSN has created the LSN Investor Database, giving fundraising executives the ability to generate a global target list of investors who are a fit for their company.  Like all databases, there is a front end of the active players – which is approximately half of our total network– which includes profiles of firms in active dialogue with the LSN Research Team and profiles of firms that have enough publicly available information/contact details to be listed.  The back-end of the database contains investors that have requested that LSN match them with fundraising companies but prefer not to be listed in the front end, investors we have identified but are not currently investing, and profiles that will be moved into the front end once we have enough data to justify value. The good news is that we think we have identified about 85% of the global early stage investors.  The functionality of the LSN Investor Database allows you to easily apply filters to generate a list of firms who are a fit for your company, which usually leaves about 300-500 firms as initial targets to begin initial qualification and potential interest.


The LSN team has conducted an analysis of hundreds of successful fundraising campaigns and has determined that, on average, a start-up company can expect to spend between $70,000 to $100,000 on their fundraising efforts.  These costs include: creating and maintaining your marketing materials and web presence, business trips, conferences, partnering road trips and other miscellaneous costs.

Campaign Component
Typical Cost
Creating and maintaining your branding, messaging, marketing collateral and web presence for a year
$25,000 – $30,000
One conference per quarter, travel and expenses
$12,000 – $20,000
1-2 week road trip per quarter, two people
$10,000 – $15,000
Global target list of investors and campaign infrastructure
$10,000 – $12,000
Legal and professional fees
$10,000 – $20,000
$67,000 – $97,000

The LSN Investor Platform is competitively priced at $6,995 for an annual subscription to fundraising executives.  This pricing is based upon making you, the fundraiser, more effective and efficient by dramatically increasing your access to global investors that are a fit for your company’s stage of development and product. Pricing justification is that the annual subscription costs:

  • 10% of typical fundraising campaign costs
  • Approximately $25 per targeted investor profile

The LSN Research Team has done the work for you to collect details regarding exact investment interests, typical allocation size, fund vintage, company management team requirements, past investment history, and personal contact details for Partners, Directors, and C-Level Executives at each firm – information that is rarely found in other investor profiles. The price of the LSN Investor Database includes: initial identification of our client’s global target list of 300-500 investors, a consultation on your introductory marketing materials (intro email and deck), campaign outreach advice, and email alerts including updates of investors added to the platform who are a fit for your company.  Additionally, the LSN Investor Platform includes an export function that provides startup CEOs with data that can be imported into a CRM system to manage outreach and track the progress of every investor relationship.  LSN has already integrated with SalesForce.com to make this process seamless for our clients.  In total, LSN offers a complete package for fundraising executives to ensure they have the strategy and investor targets necessary to conduct a successful capital raise.

The Redefining Early Stage Investments Conference Series

In addition to the LSN Investor Platform, the RESI Conference is another tool provided by LSN for fundraising CEOs. The RESI conference allows entrepreneurs to meet face-to-face with up to 16 relevant investors in one day and begin to develop a personal relationship with them. Subscribers of the LSN Investor Platform have a powerful tool that allows them dig into the investors’ profile prior to the meeting to understand the investors’ interests and preferences, greatly increasing the quality of an intro discussion and making the best use of their face-time. Using the LSN Investor Platform and RESI conference in parallel creates a tremendous value for any fundraising CEO in the early-stage life science space by not only providing the connections, but also by facilitating face-to-face interactions.

In Summary

LSN estimates that approximately 250 clients who read our CEO’s book, The Life Science Executive’s Fundraising Manifesto, purchased the database, and participated in the RESI Conference Series have raised upwards of 350 million dollars.  LSN’s value add to a fundraising CEO and scientist/entrepreneur is equivalent to 5 years’ work by 6 LSN research analysts, curating your Global Target List (GTL), which is at least 50% of the effort of raising capital – finding investors that are a fit for your stage of development and product.

The personal connection between the LSN research team and an investment firm allows LSN to capture and utilize a unique flow of information and provides an unmatched tool for fundraising CEOs to understand the players in their space, their nuanced preferences/strategies and a way to begin a dialogue with them. No other service or data provider comes close to the focused, high touch, relationship-oriented nature of data collection and maintenance.

Must See Video—CEOs explain sourcing Family Offices, Working Your Pipeline and Cost of Campaigns – Tales from the Road at RESI

13 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

More frequently than not LSN captures content through its RESI panels that hits the nail on the head. The recent “Tales from the Road” Panel does just that. It’s 6 minutes long but worth a viewing it if you are a scientist-entrepreneur or fundraising CEO. The most vital take-aways include how to source potential investors (particularly family offices), the process of “working” your pipeline of investors, and the costs associated with conducting a successful campaign.

The panel brought together successful biotech and medtech entrepreneurs to tell their stories of successfully raising capital. These are seasoned entrepreneurs who have been there done that and collectively have raised numerous private financing rounds and have exited multiple companies, with combined total deals exceeding $750 MM. They came to RESI San Diego to share their wisdom to fellow fundraising executives and provide insight in order to help their peers succeed.

Women CEOs Lead the Day at the RESI Innovation Challenge

27 Mar

By Maximilian Klietmann, VP of Marketing, LSN

Max Smile 2

RESI ended on Monday evening with over 400 attendees and over 660 partnering meetings. Additionally, 33 of the 150 biotech and medtech companies attending RESI were selected for the RESI Innovation Challenge, and competed for “RESI Cash” invested by conference attendees. Well, the winners are in:

  • The winners are global in nature, hailing from the US and Europe.
  • There was a tie for third place.
  • Women led the charge! Three of the four winning companies have women CEOs.

Scroll down to see the winning companies below (click the logos to visit company websites):



Empiriko, based in Newton, MA, is addressing several of the challenges faced by scientists, clinicians and decision-makers responsible for taking drugs from concept to commercialization. The company’s Biomimiks™ solutions can help in predicting patient/drug interaction and can be used to optimize drug designs, and improve patient outcomes.

Pam Randhawa, Founder and CEO



BIOARRAY, based in Farmington, CT, is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used.

Marcia Fournier, CEO


STC logo

STC Biologics is a biotechnology company located in Cambridge MA focusing on development of biologic drugs. The company’s portfolio of drugs includes a MAb biosimilar for Oncology as well as a re-appropriated biologic drug for the treatment of Alzheimer’s.

Magdalena Leszczyniecka, President and CEO



Multineurons, based in Switzerland, is developing medical devices for non-invasive and wireless brain-computer interface and brain diagnosis/therapy. The company’s products are based on a unique technology that evolved from more than a decade of R&D. 

Tasos Smeros, Founder & CEO

%d bloggers like this: